Recent News

• 12.06.2025 - ESMO Asia 2025 Oral Presentation: Ficerafusp alfa 750 mg QW and pembrolizumab in HPV-negative first line recurrent/metastatic head and neck squamous cell carcinoma
• 11.08.2025 - SITC 2025 Poster Presentation: Dual targeting of TGF-b and EGFR with ficerafusp alfa shows superior antitumor activity over cetuximab in KRAS/BRAF wild-type MSS colorectal cancer cell lines
• 11.05.2025 - ESMO 2025 Poster Presentation: Ficerafusp alfa-driven tumor penetration via EMT and FMT inhibition in the tumor microenviornment

Recent Filings

• 11.26.2025 - 424B5 Prospectus [Rule 424(b)(5)]
• 11.26.2025 - EFFECT Notice of Effectiveness
• 11.25.2025 - 4 Statement of changes in beneficial ownership of securities
• 11.25.2025 - 4 Statement of changes in beneficial ownership of securities
• 11.25.2025 - 4 Statement of changes in beneficial ownership of securities
• 11.25.2025 - 144 Report of proposed sale of securities
• 11.25.2025 - 4 Statement of changes in beneficial ownership of securities
• 11.24.2025 - 144 Report of proposed sale of securities
• 11.24.2025 - 144 Report of proposed sale of securities
• 11.24.2025 - 144 Report of proposed sale of securities